by Team Small News | Nov 12, 2025 | Aurobindo Pharma, Pharma
Motilal Oswal has recommended a “buy” rating for Aurobindo Pharma, with a target price of Rs 1350. The brokerage firm is optimistic about the company’s future prospects, driven by its strong product pipeline, increasing presence in the US market, and...
by Team Small News | Nov 12, 2025 | Glenmark, Pharma, Zydus
Zydus Lifesciences and Glenmark Pharmaceuticals have both received approvals from China’s National Medical Products Administration (NMPA) for their respective products. Zydus Lifesciences has been granted approval for Venlafaxine Extended-Release (ER) Capsules,... by Team Small News | Nov 12, 2025 | Cipla, Natco, Pharma
Cipla, Natco, Hetero, and Annora, four prominent Indian pharmaceutical companies, have secured significant contracts to supply generic drugs to China. This development marks a major breakthrough for Indian pharmaceutical companies in the Chinese market. The contracts...
by Team Small News | Nov 12, 2025 | Pharma, Sun Pharma
Sun Pharmaceutical Industries, one of India’s largest pharmaceutical companies, has won a significant excise refund battle. The Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) ruled in favor of Sun Pharma, dismissing a revenue demand of Rs 828 crore... by Team Small News | Nov 10, 2025 | Lupin, Pharma
Lupin, a leading pharmaceutical company, has unveiled its ambitious product pipeline and strategic targets, showcasing its commitment to driving growth and innovation in the industry. The company has outlined a robust pipeline of new products and formulations, aimed... by Team Small News | Nov 9, 2025 | Apollo Hospital, Pharma
The healthcare sector is facing a paradox in its approach to protecting life. While its primary principle is “primum non nocere” or “first, do no harm,” the sector itself is contributing to the climate crisis, which is having a devastating...